Efficient clinical evaluation of guideline quality: development and testing of a new tool by Karen Grimmer et al.
Grimmer et al. BMC Medical Research Methodology 2014, 14:63
http://www.biomedcentral.com/1471-2288/14/63TECHNICAL ADVANCE Open AccessEfficient clinical evaluation of guideline quality:
development and testing of a new tool
Karen Grimmer1*, Janine Margarita Dizon1,2, Steve Milanese1, Ellena King1, Kate Beaton1, Olivia Thorpe1,
Lucylynn Lizarondo1, Julie Luker1,3, Zuzana Machotka1 and Saravana Kumar1Abstract
Background: Evaluating the methodological quality of clinical practice guidelines is essential before deciding
which ones which could best inform policy or practice. One current method of evaluating clinical guideline quality
is the research-focused AGREE II instrument. This uses 23 questions scored 1–7, arranged in six domains, which
requires at least two independent testers, and uses a formulaic weighted domain scoring system. Following
feedback from time-poor clinicians, policy-makers and managers that this instrument did not suit clinical need, we
developed and tested a simpler, shorter, binary scored instrument (the iCAHE Guideline Quality Checklist) designed
for single users.
Methods: Content and construct validity, inter-tester reliability and clinical utility were tested by comparing the
new iCAHE Guideline Quality Checklist with the AGREE II instrument. Firstly the questions and domains in both
instruments were compared. Six randomly-selected guidelines on a similar theme were then assessed by three
independent testers with different experience in guideline quality assessment, using both instruments. Per
guideline, weighted domain and total AGREE II scores were calculated, using the scoring rubric for three testers.
Total iCAHE scores were calculated per guideline, per tester. The linear relationship between iCAHE and AGREE II
scores was assessed using Pearson r correlation coefficients. Score differences between testers were assessed for
the iCAHE Guideline Quality Checklist.
Results: There were congruent questions in each instrument in four domains (Scope & Purpose, Stakeholder
involvement, Underlying evidence/Rigour, Clarity). The iCAHE and AGREE II scores were moderate to strongly
correlated for the six guidelines. There was generally good agreement between testers for iCAHE scores,
irrespective of their experience. The iCAHE instrument was preferred by all testers, and took significantly less time to
administer than the AGREE II instrument. However, the use of only three testers and six guidelines compromised
study power, rendering this research as pilot investigations of the psychometric properties of the iCAHE instrument.
Conclusion: The iCAHE Guideline Quality Checklist has promising psychometric properties and clinical utility.
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An internet search will generally identify at least one clin-
ical practice guideline for most common health questions.
There is however, no standard approach to constructing
clinical practice guidelines [1], despite clear developmental
standards being established by internationally-respected
groups. International organisations such as the Institute
of Medicine [2] (IOM), World Health Organisation [3]
(WHO), National Institute for Health and Clinical Excel-
lence [4] (NICE) and Scottish Intercollegiate Guideline
Network [5] (SIGN) all provide readily available resources
to aid developers in producing high quality evidence based
guidelines. However despite these valuable resources, vari-
able quality clinical guidelines continue to be developed
by many organisations in different countries, as the de-
mand for evidence-based practice aids grows globally. For
instance in Australia, more than 100 organisations are
currently listed on the National Health and Medical
Research Council (NHMRC) Clinical Practice Guidelines
Portal as having an interest in guideline development [6].
A similar situation would be expected in most developed
countries.
However, no matter how well constructed a clinical
guideline is, access to a high quality evidence source
alone does not necessarily result in translating that evi-
dence into clinical practice. There is a large body of lit-
erature regarding barriers to evidence implementation
particularly by clinicians. Barriers for clinician end-users
can be grouped into individual beliefs, behaviours, disin-
centives to change, organisational and structural sup-
ports, education and cultural beliefs [7-9]. Globally, and
across health disciplines, time, knowledge about the ele-
ments of quality guidelines, demonstrable incentives and
accessibility to information on guidelines are universal
barriers to implementing evidence in clinical guidelines
into practice [10-13].
Thus clinicians wishing to identify the best quality
clinical practice guidelines that could assist their clinical
decisions, are faced with many difficult questions, such
as ‘where to go for information’, ‘which guideline to
choose from the many of variable appearance and cred-
ibility’, ‘how to efficiently choose a good guideline’, and
‘how to determine its methodological rigour, relevance to
clinical settings and applicability to clinical questions’. Lack
of simple and efficient solutions to these questions may
undermine commitment by clinicians, policy-makers and
managers to putting best current evidence into practice.
There is no standard approach to assessing clinical practice
guideline quality, which addresses the needs of researchers,
methodologists, educators, clinicians, policy-makers and
managers. In the literature, the most commonly-reported
guideline quality instrument is the AGREE instrument
[14,15]. This was developed primarily for guideline devel-
opers and researchers, to outline and measure coreelements of guideline construction and implementa-
tion. The AGREE instrument (initially AGREE I [14],
now AGREE II [15]) consists of six domains of ‘scope
and purpose’, ‘stakeholder involvement’, ‘rigour of de-
velopment’, ‘clarity of presentation’, ‘applicability’, ‘editorial
independence’. The AGREE II instrument [15] contains
23 questions in these domains, with each question scored
using a 1–7 scale of perceived compliance. To calculate
AGREE II instrument scores requires two or more testers
(i.e., AGREE cannot be completed by only one tester), and
a scoring rubric is provided to weight domain scores,
depending on how many testers participate [15]. The reli-
ability of the AGREE II instrument has been variably re-
ported [16,17]. Recently a Guidelines International Network
(GIN) panel [1] suggested that there were different quality
domains (composition, decision-making process, conflicts
of interest, guideline objective, development methods, evi-
dence review, basis of recommendations, ratings of evi-
dence and recommendations, guideline review, updating
processes, and funding). However to date, no scoring sys-
tem has been proposed for the GIN approach.
Our team from the International Centre for Allied
Health Evidence (iCAHE) (University of South Australia,
Australia) commenced a Guidelines Clearinghouse initia-
tive on its website [18] in 2008, by collating clinical guide-
lines which address conditions of interest to iCAHE
members (namely clinicians, managers and policy makers).
While the primary end-users of the Guideline Clearing
House were allied health clinicians, policy-makers and
managers (in line with the iCAHE mission and funding im-
peratives), the Guideline Clearing House is also accessed
by other health disciplines, as well as educators and re-
searchers. The aim underpinning the Guidelines Clearing
House initiative was to remove as many barriers as possible
for website end-users regarding access to, and uptake of,
good quality evidence-based information. This meant that
not only should we make it as simple as possible for users
to access a wide range of clinical guidelines, but also to
provide an indication of methodological quality. We also
recognised that we should provide a way for our website
end-users to score the methodological quality of other
guidelines that they might find through their own efforts.
During the development of the iCAHE Guideline
Clearing House, discussions held with Australian policy
makers, educators, clinicians and administrators identi-
fied the need for a psychometrically sound, efficient,
simply scored quality assessment instrument that ad-
dressed important guideline quality criteria, and assisted
end-users to make decisions on their own, in minutes,
regarding clinical guideline quality. Consistent feedback
was that the AGREE instrument was not appropriate in
busy clinical settings, due to its number of questions,
the complexity of the 1–7 scoring system, and the re-
quirement for multiple testers to make a judgment on
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that a clinically-oriented guideline quality assessment in-
strument should not concurrently consider relevance or
applicability of recommendations to local clinical prac-
tice contexts. In clinical and policy settings it was essential
to separate these issues. Once a guideline of good quality
had been established, discussions could then occur regard-
ing contextualisation to local practice settings, and then
implementation.
This paper describes the development and psychomet-
ric testing of a simple, single-user clinical guideline
methodological quality checklist designed for busy clin-
ical and policy settings.
Methods
Ethics
Ethical approval was provided by the Human Research
Ethics Committee, University of South Australia as part
of a larger evidence-implementation project (P208/09).
Developmental work
Elements of clinical guideline quality which were consid-
ered to be important by clinicians, managers and policy-
makers were identified during the construction of the
iCAHE Clinical Guideline Clearinghouse. Moreover, com-
mon methodological quality elements were identified from
material developed by internationally-recognised guideline
developers [2-6]. A draft 14 item instrument was con-
structed using binary assessment for each item (Yes, there
was clear evidence that an item had been addressed, or
No, there was not clear evidence that an item had been
addressed). This is the same scoring approach as used in
the PEDro critical appraisal instrument for randomised
controlled trials [19], which would be familiar to many
end-users of the iCAHE website via its Critical Appraisal
Tools page [18]. The draft clinical guideline critical ap-
praisal instrument was made available for public comment
on the iCAHE website [18] in 2009 for three months. No
changes to its format were suggested by 32 respondents,
and the resultant iCAHE Guideline Quality Checklist has
been in use since then, in its original form (see Additional
file 1).
Research questions
The following questions were asked during psychometric
testing of the iCAHE Guideline Quality Checklist:
1. What are the psychometric properties (content
and construct validity, and inter-tester reliability)
of the iCAHE Guideline Quality Checklist,
when compared with the AGREE II
instrument [15]?
2. Can an inexperienced tester use the iCAHE
Guideline Quality Checklist effectively?3. Does the iCAHE Guideline Quality Checklist have
similar clinical utility to the AGREE II instrument?
Guideline assessment instrument scoring
Choosing the AGREE II instrument for validation pur-
poses imposed constraints on what comparative testing
could be undertaken. The AGREE II scoring rubric re-
quires two or more testers, to produce tester-weighted
scores for each of six domains. These scores provide no
measure of variability, and individual AGREE II scores
are not available. Thus tester differences in domain
scores cannot be calculated. Moreover, the developers
recommended that a total AGREE II score should not
be calculated [15]. Conversely, the iCAHE instrument is
designed to be scored by one tester, thus multiple tester
data could be described by central tendency (average),
Standard Deviations could be calculated and tests for
homogeneity undertaken to assess tester differences.
Psychometric testing
Content validity was assessed by aligning the questions in
the iCAHE Guideline Quality Checklist with those in the
AGREE II instrument, and identifying which of the AGREE
II domains were assessed by the iCAHE instrument.
Construct validity was tested by the correlation between
guideline quality scores from the iCAHE instrument and
the AGREE II instrument. For this purpose, six clinical
guidelines related to the management of traumatic brain
injury were assessed. These guidelines were randomly se-
lected from 53 systematically-identified guidelines collated
for a large quality and safety project. Pearson correlation
coefficients and 95% Confidence Intervals were applied
to determine the strength of correlation between overall
scores for iCAHE and AGREE II instruments, as well as
individual testers’ scores using the iCAHE instrument.
Tester experience was assessed by employing three
purposively-sampled testers with different experiences in
guideline quality assessment. Each tester assessed the
methodological quality of each guideline independently,
using both the AGREE II and iCAHE checklists. Testers
determined their own order of assessing guidelines, and
with which tools. Tester 1 was an experienced guideline
writer, and a developer of the iCAHE checklist; Tester 2
had moderate experience in guideline writing, and had
some experience of using the iCAHE checklist, but no
involvement with its development; and Tester 3 was a
novice guideline assessor with no experience in using ei-
ther instrument. No training was provided on how to
use either instrument, and scores were not discussed.
Inter-rater reliability was determined by assessing differ-
ences between testers’ scores on the iCAHE instrument.
Tester differences in scoring the AGREE II instrument do-
mains could only be considered using the testers’ raw scores
for each question (which is not recommended practice).
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The raters recorded the time spent scoring each guide-
line with each instrument. A semi-structured exit inter-
view was conducted by an independent researcher with
each individual rater, to identify their perspectives on the
simplicity of scoring using each instrument, their prefer-
ences, and what underpinned these.
Data management
iCAHE instrument scores were not reported per domain
(as is required for the AGREE II instrument), as the
intention of this instrument was to provide an efficient,
global quality rating process per guideline. Thus, for the
iCAHE Guideline Quality Checklist, percentage total
quality scores were calculated per guideline per tester by
converting ‘yes’ and ‘no’ responses to 1 or 0 respectively,
then summing the total number of Yes scores, dividing
this by the maximum possible score (14) and expressing
this as a percentage.
The AGREE II checklist comprises six domains, each
containing between 2 and 8 questions. Each question is
scored with 7-point scale. Domain scores are calculated
using the AGREE II guideline scoring rubric (agree@mc-
master.ca) [15]:
Obtained score – Minimum possible score
Maximum possible score – Minimum possible score
The variability of decision-making is not captured in
the AGREE II rubric (i.e., a single value is reported with
no information on range, or differences between testers).
Although it is not recommended [15], we calculated a
total AGREE II score for the purpose of this paper, by
applying the same scoring rubric as above to all 23 ques-
tions, and expressing this as percentage of the possible
total agreement score. This standardised comparison
with the iCAHE Guideline Quality Checklist percentage-
of-total scores. We also considered the raw tester scores
for each AGREE II question to assess tester experience
in determining AGREE II score distributions.
Data analysis
The average iCAHE instrument scores (SD) for the three
testers, and the domain and total AGREE II scores, were
described for each guideline. Significant differences in
the iCAHE scores (p < 0.05) between testers across the
guidelines were determined using ANOVA models. It
was not possible to determine the impact of tester ex-
perience on AGREE II domain or total scores because of
the lack of a measure of variability (as per the scoring
rubric) [15]. Construct validity was reported as Pearson’s
correlations (95% Confidence Intervals) between percent
of total scores for each guideline on each instrument, for
pairs of testers. The average time (Standard Deviation)taken to score each guideline with each instrument was
calculated per tester, and differences between testers and
instruments were determined using ANOVA models.
Microsoft Excel [20] and SAS [21] statistical software were
used for these data analyses.
Given the small number of testers (3) and guidelines
(6) used for this study, it was possible that unacceptable
Type I and II errors has been incurred. A post-hoc power
calculation was conducted using G-Power [22], based on
an ANOVA repeat measures between factors model (α =
0.05, 18 guidelines, three testers, two instruments, 0.4 ef-
fect size, 0.7 correlation) to determine the degree of con-
fidence which could be placed in the findings.
Utility




Details of the six randomly-selected clinical guidelines are
provided in Table 1.
Critical appraisal elements
The iCAHE instrument included questions that addressed
four of the AGREE II domains (Scope and Purpose,
Stakeholder Involvement, Rigour of Development and
Clarity of Presentation). The iCAHE checklist deliberately
did not address Applicability and Independence, as this
was outside its remit to assess guideline construction
quality. The AGREE II instrument did not include ques-
tions which addressed the new iCAHE instrument do-
mains of Currency, Availability or Summary.
Total quality scores
The percentage of total scores for each guideline from
the iCAHE and AGREE II instruments are reported in
Table 2. The six weighted domain scores for the AGREE
II instrument are reported per guideline in Table 3. Higher
percentage of total scores on both instruments, and higher
domain scores on AGREE II, indicate better guideline
quality. The AGREE II percentage of total score was sub-
stantially less than the iCAHE total percentage score for
four of the six guidelines, although the scores were similar
for SIGN [28] and Golisz [26]. Golisz [26] and AANN and
ARN [23] had identical average iCAHE total scores, but
differing scores for the AGREE II instrument. On closer
inspection, the AANN and ARN [23] guideline had lower
AGREE II scores for domains 5 and 6, than Golisz [26]
(Applicability, and Editorial Independence, respectively).
The questions in these domains are not represented in the
iCAHE checklist (Table 4), which would perhaps account
for the differences between instruments in the percentage
of total possible scores reported in Table 2.
Table1 Descriptions of guidelines used for psychometric testing
Guideline reference Purpose
AANN and ARN (2011) Care of the Patient with Mild Traumatic Brain
Injury: AANN and ARN Clinical Practice Guideline Series [23] Country: USA
This guideline was developed by the American Association of
Neuroscience Nurses and the Association of Rehabilitation Nurses, and
provides recommendations for nurses and institutions based on latest
evidence for mild traumatic brain injury.
Barbosa (2012), Evaluation and management of mild traumatic brain
injury: An eastern association for the surgery of trauma practice
management guideline [24] Country: USA
This guideline updates an earlier 2001 edition. Recommendations for the
management of mild traumatic brain injury are aimed at clinicians
(primarily medical staff) working in acute care.
Brain Trauma Foundation (2012), Guidelines for the Acute Medical
Management of Severe Traumatic Brain Injury in Infants, Children, and
Adolescents-Second Edition [25] Country: USA
This guideline updates an earlier 2003 edition. Recommendations for the
management of infants, children and adolescents with severe traumatic
brain injury are aimed at acute care clinicians (primarily medical staff).
Golisz (2009), Occupational therapy practice guidelines for adults with
traumatic brain injury [26] Country: USA
This guideline is aimed at occupational therapists. Recommendations are
made for the evaluation, acute care and rehabilitation of adults with
traumatic brain injury.
National Institute of Health & Clinical Excellence (NICE) (2007), Head
injury: Triage, assessment, investigation and early management of head
injury in infants, children and adults [27] Country: UK
This guideline is the update of an earlier 2003 edition. This guideline
addresses assessment, investigation and early management of head
injury. Separate advice is provided for adults and children (including
infants).
Scottish Intercollegiate Guidelines Network (SIGN) (2013).Guidelines for
traumatic brain injury rehabilitation [28] Country: UK (Scotland)
This guideline makes recommendations on the early management of
patients with head injury, focusing on topics of importance throughout
National Health Service, Scotland. Recommendations are made for the
management of traumatic brain injury in adults and children
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Considering the quality ranking of each guideline with
each instrument, the SIGN guideline [28] was ranked best
overall by both instruments, and in the AGREE II domains
(ranking first in Domains 2–6 (Stakeholder Involvement,
Rigour of Development, Clarity of Presentation, Applic-
ability and Editorial Independence) and second in Domain
1 (Scope and Purpose)). The NICE guideline [27] was the
second best overall ranked on both instruments, and it
ranked 2 or 3 for all six AGREE II domains. In subsequent
decreasing ranked order of total iCAHE and AGREE II
scores, and the AGREE II domains, were the Brain
Trauma Foundation guideline [25] and then Golitz [26].
The rankings of the remaining two guidelines (BarbosaTable 2 Average % total iCAHE scores (Standard
Deviation) (over the three testers) for the six guidelines,
and % total score considering all 23 questions in the
AGREE II instrument, using the scoring rubric [15]
Guideline iCAHE Rank* AGREE II Rank
Total % score Total % score§
AANN and ARN [23] 73.8 (4.1) 4 55.9 6
Barbosa [24] 71.4 (0.0) 5 56.7 5
Brain Trauma




Golisz [26] 73.8 (14.9)+ 4 74.5 4
NICE [27] 97.6 (4.1) 2 84.9 2
SIGN [28] 100.0 (0.0) 1 97.3 1
*The guidelines are ranked by quality for each instrument.
§NB The % total AGREE II scores have no measure of variance.
+Significant differences between testers (p < 0.05) are noted in italics for the
iCAHE instrument.[24], AANN and ARN [23]) were reversed in iCAHE and
AGREE II, however they were both poorly ranked irre-
spective of which quality assessment instrument was used.
Differences between tester iCAHE scores
There was total agreement between testers using the
iCAHE instrument for three guidelines of different qual-
ity (SIGN [28] (high quality), Brain Trauma Foundation
[25] (moderate quality) and Barbosa [24] (poorest quality).
There was some disagreement between testers (SD 4.1)
for two guidelines (NICE [27] (moderate - good quality),
and AANN and ARN [23] (poorer quality). There was
however, a significant difference between testers for one
poorer quality guideline (Golisz [26], with the novice
tester scoring significantly higher than the other testers.
Prospective scoring bias
Apart from SIGN [28], no other guideline had sequen-
tially similarly-scaled scores for subsequent domains
(See Table 3). Thus a high score for Domain 1 (Scope
and Purpose) was not an indication of overall guideline
quality, and did not necessarily result in high scores for
subsequent domains. This suggests that there was little
or no sensitivity to initial high or low scoring by the tes-
ters. As an example, whilst most guidelines had high Do-
main 1 scores (Scope and Purpose), most had low scores
for Domain 2 (Stakeholder Involvement) and Domain 5
(Applicability). Half the guidelines had low scores for
Domain 6 (Editorial Independence), indicating that these
areas require further attention by guideline developers.
On the other hand, Domain 1 (Scope and Purpose), Do-
main 3 (Rigour of Development) and Domain 4 (Clarity
Table 3 Scaled domain scores (%)* derived from three testers, as per AGREE II scoring rubric [15]
Domain1 Domain2 Domain3 Domain4 Domain5 Domain6
AANN and ARN Clinical Practice Guideline [23] 66.7 64.8 45.8 77.8 9.7 41.7
Barbosa (Eastern Association of the Surgery of Trauma) [24] 81.5 29.6 49.3 75.9 27.8 36.1
Brain Trauma Foundation [25] 92.6 57.4 89.6 92.6 26.4 80.6
NICE [27] 98.1 92.6 94.4 92.6 48.6 83.3
SIGN [28] 98.1 100.0 100.0 96.3 95.8 88.9
Golisz [26] 100.0 61.1 76.4 90.7 51.4 22.2
*NB The % domain scores have no measure of variance.
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that the testers all considered that they well explained.
Construct validity
There was a strong positive correlation between the per-
centage of total scores across six guidelines and three
testers, when comparing the two instruments (r = 0.89,
df = 4, p < 0.05) (critical r value = 0.812). This finding,
and the consistency of quality rankings reported in
Table 2 between the two instruments supports the con-
struct validity of the iCAHE instrument in capturing the
important items of guideline quality described in the
AGREE II instrument. Considering percentage of total
iCAHE scores for pairs of testers, there was a stronger
positive correlation between Testers 1 and 2, than be-
tween either Tester 1 or 2, and Tester 3 (See Table 5). Less
convincing correlations were evidenced by broader 95%
CI round the Pearson r correlation coefficients.
Making definitive judgements
The iCAHE instrument requires a definitive response to
each of 14 questions (either Yes or No). There is no
other scoring option. On the other hand, the AGREE II
scale is divided into low (1 = “strongly disagree”), 2–3,
(4 =middle point “neither agree nor disagree”), 5–6 and
the top end of the scale (7 = “strongly agree”). Thus
AGREE II instrument provides two definitive options
(No = 1 and Yes = 7) with ranked ‘disagree’ through to
‘agree’ options in between (2–6). Considering the defini-
tive options (1 or 7) within the raw scores for the 23
AGREE II questions, for each guideline, there was consid-
erable variability between testers, as outlined in Figure 1.
Moreover, the least experienced researcher, Tester 3, did
not use the bottom end of the scale (1–3) as much as the
more experienced researchers did, particularly Tester 2.
All three testers similarly used the top end of the scale
(suggesting that either it is easier to make a judgement
that a guideline complied with an item than not, or that
the guidelines were generally compliant with the AGREE
II questions). The moderately experienced researcher,
Tester 2, seemed to dominate the ends of the scale more
than Testers 1 and 3. This could perhaps be explained if itwas assumed that Tester 1 understood the subtleties of
the AGREE II criteria better than the other testers, and
could sensitively score the quality of compliance with each
item, whilst Tester 3 in her inexperience may have ‘hedged
her bets’ and scored more towards the middle of the scale
when a definitive 1 or 7 answer was not obvious.
Post-hoc power calculations indicated that this study
of the psychometric properties of the new iCAHE in-
strument was under-powered (0.49) and should there-
fore be considered as a pilot. To be better powered (say
at 0.8), future studies of the psychometric properties of
the iCAHE instrument should include at least twice as
many testers, and guidelines. Moreover, the guidelines
chosen for future testing should include more poorer
quality ones to ensure that the iCAHE instrument is
sensitive across the spectrum of quality.
Utility
All three raters indicated that the iCAHE tool was sim-
pler and quicker to use than the AGREE II tool. Simpli-
city was identified in the number of iCAHE assessment
questions (14) and the binary scoring options, compared
with the 7-point scale for 23 questions in AGREE II.
Whilst there were minimal within-tester differences in
time taken to score with iCAHE, or AGREE II instru-
ments, there were significant between-tester differences
(p < 0.05) when using either instrument. Not surprisingly,
the novice tester was the slowest on both instruments, tak-
ing on average, five minutes per guideline (range 3–7 mi-
nutes) with the iCAHE instrument, and up to 20 minutes
per guideline using the AGREE II instrument (average
18 minutes (15–20 minutes range)). The most experienced
tester consistently took 3–4 minutes per guideline using
the iCAHE instrument, and 10–12 minutes per guideline
using the AGREE II instrument. Tester 2 scores sat in be-
tween (4–6 minutes with iCAHE, 12–16 minutes with
AGREE II). All testers indicated that they found the better
quality guidelines easier and quicker to score than the
poorer quality ones, because compliance with assessment
items were more readily identifiable and reported in the
better quality guidelines. However such ease of scoring
was not reflected in the time taken. All testers indicated
Table 4 Comparison of questions in AGREE II and iCAHE instruments relevant to domains
iCAHE AGREE II
AGREE II Domain 1:
Scope & Purpose
Q13 Are the purpose and target users of the guideline stated? Q1. The overall objectives of the guideline are
specifically described
Q2. The health questions covered by the guideline are
specifically described
Q3. The population to whom the guideline is meant to
apply is specifically described
Q6. The target users are clearly defined
AGREE II Domain 2:
Stakeholder involvement
Q11. Are the developers clearly stated? Q4. The guideline development group includes
individuals from all relevant professional groups
Q12. Does the qualifications and expertise of the guideline
developers link with the purpose of the guideline and its end
users?
Q5. The views and preferences of the target population
have been sought
Q7. Does the guideline provide an outline of the strategy used
to find underlying evidence?
Q7. Systematic methods were used to search for the
evidence
Q8. Does the guideline use a hierarchy to rank the quality of
the underlying evidence?
Q8. The criteria for selecting the evidence are clearly
described
Q9. Does the guideline appraise the quality of the evidence
which underpins its recommendations?
Q9. The strengths and limitations of the body of
evidence are clearly described
Q10. Does the guideline link the hierarchy and quality of
underlying evidence to each recommendation?
Q10. The methods for formulating the
recommendations are clearly described
AGREE II Domain 3:
Rigour of Development
Q11. The health benefits, side effects and risks have
been considered in formulating the recommendations
Q12. There is an explicit link between the
recommendations and the supporting evidence
Q13. The guideline has been eternally reviewed by
experts prior to its publication




Q4. Is there a date of completion available?
Q5. Does the guideline provide an anticipated review date?
Q6. Does the guideline provide dates for when literature was
included?
AGREE II Domain 4:
Clarity of Presentation
Q14. Is the guideline readable and easy to navigate? Q15. The recommendations are specific and
unambiguous
Q16. The different options for management of the
condition or health issues are clearly presented
Q17. Key recommendations are easily identifiable
AGREE II Domain 5:
Applicability
Q18. The guideline describes facilitators and barriers to
its application
Q19. The guideline provides advice and/or tools on
how the recommendations can be put into practice
Q20. The potential resources implications of applying
the recommendations have been considered
Q21. The guideline presents monitoring and/or
auditing criteria
AGREE II Domain 6:
Editorial Independence
Q22. The views of the funding body have not
influenced the content of the guideline
Q23. Competing interests of guideline development
group members have been recorded and addressed
New iCAHE instrument
Domain: Availability
Q1. Is the guideline readily available in full text?
Q2. Does the guideline provide a complete reference list?
New iCAHE instrument
Domain: Summary
Q3. Does the guideline provide a summary of its
recommendations?
Grimmer et al. BMC Medical Research Methodology 2014, 14:63 Page 7 of 10
http://www.biomedcentral.com/1471-2288/14/63
Table 5 Paired-tester correlations between % total scores
on the iCAHE instrument (Pearson r values, 95% CI)
iCAHE checklist Tester 1 Tester 2 Tester 3
Tester experience
level High Moderate Low
Tester 1 0.97 (0.75 to 0.99) 0.75 (-0.16 to 0.98)
Tester 2 0.86 (0.16 to 0.98)
Tester 3
NB non-significant correlations are indicated by italics.
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AGREE II instrument was spent in determining the appro-
priate score on the 7-point scale.
Discussion
This paper reports promising psychometric properties of a
new, clinically-focused clinical guidelines quality assess-
ment instrument (the iCAHE Guideline Quality Scoring
Instrument), compared with the research-focused AGREE
II instrument. Despite the underpowered nature of this
study, the findings from three testers with different
experiences, assessing six clinical guidelines of moder-
ate to good quality, suggest that the iCAHE critical
appraisal instrument has the potential for good clin-
ical utility and sound psychometric properties. It thus
represents a viable critical appraisal approach for clin-
ical guidelines for time-poor clinicians, policy-makers
or managers.
To establish its psychometric properties and clinical
utility, the iCAHE Guideline Quality Checklist was com-
pared with the widely cited clinical guideline quality as-
sessment instrument, AGREE II [15]. This instrument is
not designed for, nor intended to be used by, clinicians,
policy-makers or managers, as evidenced by the number
of included questions, and its scoring system. There was
however, correlation of question purpose between the two
instruments in four domains (Scope & Purpose, Stakeholder
































Figure 1 Frequency of use of AGREE II item 7-point scale,
comparing the three testers’ aggregated raw scores for all
six guidelines.The iCAHE instrument included three additional domains
(Currency, Availability, and Summary), and the only do-
mains which were covered by the AGREE II instrument
that were not addressed by the iCAHE instrument were
Applicability and Editorial Independence. These had been
purposely excluded from the iCAHE instrument during
its development as being ‘next steps’ in contextualisation
and implementation.
Six randomly-selected clinical guidelines in a similar
diagnostic area (brain injury) [23-28] were used in this
research. The quality of these guidelines ranged from
moderate to good, and thus they may not have presented
sufficient challenge in guideline quality assessment to es-
tablish the sensitivity of the iCAHE instrument across a
range of guideline quality. Future research should not only
include more guidelines and testers, but should include
guidelines with poor quality, to ensure comprehensive op-
portunities to test the sensitivity of the iCAHE instrument.
Congruent with its application to busy clinical and policy
environments, the 14 item iCAHE instrument uses a sim-
ple, binary form scoring system which can be readily
summed and reported as a total raw score (or percentage)
of 14. Time taken to score a clinical guideline approxi-
mates 3–5 minutes irrespective of the skill of the assessor.
On the other hand, the AGREE II score requires value
judgement using a 1–7 level scoring system, multiple as-
sessors and the application of a scoring rubric to determine
quality scores in six domains of 23 questions. Moreover, it
is not recommended that a total AGREE II score is calcu-
lated, or raw scores used, although this was done for this
paper to facilitate comparison between instruments. We
believe that evidence supporting our claims of the clinical
utility of the iCAHE instrument is provided in Figure 1,
which outlines the difficulty that the novice guideline
assessor had in making decisions about scoring in the
AGREE II scale midpoints (3–5). Given this and the
non-significant differences in iCAHE scores found be-
tween the three testers (moderate to excellent agreement
for 17 of the 18 guideline assessments), it seems that the
iCAHE instrument could be applied by anyone, with no
prior experience or training. We also suggest that the
iCAHE Guideline Quality Checklist may be simpler, more
efficient and less prone to ‘guessing’ than the AGREE II
instrument.
Conclusion
The ultimate goal of evidence-based practice is to improve
the quality and safety of health care. For this to occur, the
current best evidence should be presented in a believable
and readily implementable form for clinicians, policy-
makers and managers. Clinical practice guidelines provide
a useful mechanism to present current best evidence to
clinical and policy end-users to ensure that their decision
making is evidence-based. To be useful however, these
Grimmer et al. BMC Medical Research Methodology 2014, 14:63 Page 9 of 10
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their quality needs to be able to be efficiently assessed by
busy end-users.
We propose that the iCAHE Guideline Quality Scoring
Instrument provides a clinically-acceptable alternate to
the AGREE II instrument to assess the quality of clinical
guidelines, in clinical practice and policy settings. It can
be completed relatively quickly by one individual, and it
does not require specific training prior to use. It also
does not pose the user with questions regarding ‘partial
compliance’ with quality assessment items (as required
in the AGREE II instrument) and it does not require a
scoring rubric to produce an overall scaled score.
Once a guideline has been identified as having good
methodological quality using the iCAHE Guideline Quality
Scoring Instrument, end-users are encouraged to con-
sider relevance, applicability and implementation issues.
We believe that this is a simpler, staged approach for
time-poor end-users in clinical environments than consid-
ering all these elements at the one time. Unless a clinical
practice guideline has good methodological quality, there
is little point in considering how to contextualise or im-
plement it.
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